
Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to show a rise in quarterly revenue when it reports results on May 14 (estimated) for the period ending March 31 2025
The Iselin New Jersey-based company is expected to report revenue of $702.6 thousand, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Outlook Therapeutics Inc is for a loss of 60 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Outlook Therapeutics Inc is $9.50, above its last closing price of $1.53.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.69 | -0.77 | 0.72 | Beat | 192.9 |
Sep. 30 2024 | -0.86 | -0.83 | 0.76 | Beat | 191.1 |
Jun. 30 2024 | -1.02 | -1.00 | -0.83 | Beat | 16.8 |
Mar. 31 2024 | -0.96 | -0.85 | -1.55 | Missed | -82.4 |
Dec. 31 2023 | -0.92 | -1.00 | -0.80 | Beat | 20 |
Sep. 30 2023 | -1.16 | -1.17 | -1.00 | Beat | 14.9 |
Jun. 30 2023 | -0.82 | -1.03 | -1.60 | Missed | -55.6 |
Mar. 31 2023 | -1.19 | -1.30 | -0.60 | Beat | 53.8 |
This summary was machine generated May 12 at 13:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)